Pharmacovigilance and Drug Safety

Amit Singh, Dr. Neeraj Bhandari, Ashish Kumar, Ajay Kumar, Jyoti Devi, Shruti Tugnotia

Amit Singh, Student of B Pharmacy

School of Pharmacy, Arni University

Kathgarh, Indora, Distt. Kangra H.P Pincode 176401.

Abstract: Pharmacovigilance keeps an eye out for and assesses adverse drug reactions (ADRs), which help ensure that drugs are used safely and appropriately. Even with the extensive testing that medications go through before being approved, some side effects might not be seen until the medication is taken widely. One important way to find new safety signals is through the spontaneous reporting of adverse drug reactions (ADRs) by patients and healthcare providers. Understanding the safety profile of medications is further assisted by observational studies and post-marketing surveillance that make use of real-world data.

Introduction: The World Health Organization defines pharmacovigilance, commonly referred to as drug safety, as the science and actions pertaining to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. [1,2].

While a medicine is being developed, only rudimentary safety data about the product is available to us. The actual use of medications in clinical practice necessitates ongoing observation and assessment, which must be tracked by a robust pharmacovigilance system. Throughout the product lifecycle, post marketing pharmacovigilance and clinical trial safety are equally important. [3].

Reaffirmed the necessity of prompt action with relation to the quick distribution of data on adverse drug reactions (ADRs). This ultimately resulted in the World Health Organization (WHO) establishing a pilot study for global drug monitoring in 1968. [4].

The occurrences were more widely recognized and reported as a result of ADRs' expertise. ADRs account for 12% of admissions in wealthy nations, making them the fourth and sixth most

frequent cause of death. [5].

A notable increase in the number of commercially accessible medications and the quick creation of novel molecules for diseases that were previously incurable, as well as new therapeutic options for other common pathologies, are other potential factors. This may result in a lack of awareness among medical practitioners regarding the possible negative consequences of drug-drug interactions or the contraindications of some medications brought on by inappropriate use. [6-8].

Additionally, because of their higher absorption, generic medications have led to an increase in individuals experiencing adverse drug reactions or not responding to treatment. [9-10].

the creation of theories that prompt additional research to support or contradict any potential dangers associated with drug usage, any potential modifications in the packaging insert and provide the most recent product information. [11].

Lack of knowledge (it is thought that only serious adverse reactions should be reported), lack of interest or time, indifference to the issue, uncertainty regarding the causal relationship between a drug and an ADR, and the false belief that only safe drugs are marketed are the main causes of under-reporting, according to literature data. [12].

Pharmacovigilance and Drug Safety: The research and practices involved in identifying, evaluating, comprehending, and averting adverse reactions or additional problems pertaining to medications are referred to as pharmacovigilance, or drug safety. It guarantees the safest and most effective utilization of medications [13]. This procedure entails keeping an eye on, recognizing, and assessing adverse drug responses, guaranteeing patient safety, and preserving the risk-benefit ratio of medications over the course of their lifetime. The World Health Organization defines pharmacovigilance, commonly referred to as drug safety, as the research and practices involved in identifying, evaluating, comprehending, and preventing side events or other issues associated to drugs [14]. The science of gathering, tracking, analyzing, and evaluating data from patients and healthcare professionals regarding the negative effects of prescription and over-the-counter medications, vaccines and biologicals, blood products, medical devices, herbal remedies, and other complementary and traditional medicines in order to find new information about side effects related to their use and take the appropriate precautions to protect patients is known as pharmacovigilance [15]. By managing diseases, medications enhance quality of life; nevertheless, in spite of all of these advantages, medications can have negative side effects that can lead to serious morbidity and mortality. There is always a chance of adverse interactions when many medications are prescribed. Additionally, A patient may react differently to a medicine and experience distinct side effects because of variations in their genetic makeup. A notable example would be acute hemolysis that occurs in patients who have a deficiency in glucose-6-phosphate dehydrogenase (G6PD) after they are exposed to primaquine, a medication that is frequently recommended to treat malaria. One of the top ten causes of death is adverse drug reactions (ADRs). To protect the public's health, risk management and drug safety monitoring are essential. A comprehensive evaluation of the fresh data produced by pharmacovigilance efforts is necessary to encourage the safe use of the medications. It is imperative for pharmaceutical businesses to have effective systems and procedures for monitoring drug safety. One essential element in assessing the benefit to risk ratio of medications is pharmacovigilance. To create a successful pharmacovigilance system worldwide, patients, pharmaceutical companies, regulatory bodies, and healthcare professionals must work closely together. Following the publication of a report in the Lancet, the first committee established to oversee drug safety was in response to the death of a 15-year-old girl in 1848 who had undergone chloroform anaesthesia for the removal of an ingrown [16]. A plastic anaemia instances linked to chlorampheni use [18].

In 1950, reports of col were made in the United States. Consequently, a Blood Dyscrasia Registry was established by the American Medical Association's Council on Drugs.

Food as well

In 1961, the Drug Administration (FDA) started compiling reports of all kinds of adverse drug reactions in a systematic manner. In 1961, Thalidomide was removed from the market due to its link to congenital deformity in newborns. For a medicine with a particular risk that requires mitigation, the FDA in the US mandates Risk Evaluation and Mitigation Strategies (REMS) [19]. Examples include the antiretroviral pregnancy registry, the isotretinoin pregnancy prevention initiative, and REMSs submitted for the use of prohibited medications mandates specific actions or adherence to a protocol from a sponsor in order to ensure that the drug's risk-benefit ratio is maintained during marketing [20].

Partner in Pharmacovigilance: The main players in pharmacovigilance must work closely and effectively together to manage the problems pertaining to medication use. The persons in charge should work together to foresee, clarify, and address the ever-increasing needs and expectations of the general public, legislators, health administrators, and policy officials. However, without robust and all-encompassing systems that enable

such relationships, there is little chance that this will occur. Usually, the challenges include a lack of funding, political backing, training, and, most importantly, scientific infrastructure.
For the science and practice of pharmacovigilance to advance in the future, it is imperative that they be understood and addressed [21].

1. Health care professional
2. Individuals
3. Academic and Medical Facilities
4. The Pharmaceutical Sector
5. WHO Quality Control and Safety Pharmaceuticals
6. National Pharmacovigilance Centers (NPC)
7. Uppsala Monitoring Center (UMC)
8. Others

Healthcare workers: Doctors, Dentists, Pharmacists, and Nurses must all use medications safely. It is their duty to alert their patients to any concerns regarding drug therapy, such as:

The nature of illness, the intended usage of the medication, and any possible hazards associated with its administration. They also have the further duty of making sure their patients comprehend the nature of the treatments they are receiving [22].

Individuals: In the UK, the YCS (yellow card system) was introduced in 2005 as a means for patients to submit potential ADRs to regulatory bodies. Patients in the UK, Sweden, Australia, and the USA reported ADRs in 2009 at a rate of 18% to 20%. They did so via the mail, the internet, and the phone to raise awareness of the evaluation. These techniques showed that knowledge was low and could be raised, and they were deemed appropriate for the general community in the UK [23,24,25].

Academic and Medical Facilities: Pharmacovigilance has emerged as a clinical field as a result of partnerships between the pharmaceutical sector, academia, and drug regulatory agencies. Few medical schools offer ADR-related instruction to medical students as part of their pharmacology courses. Therefore, the vast majority of medical graduates could not have sufficient knowledge about medication adverse drug reactions.

The Pharmaceutical Sector: Every pharmaceutical company has a crucial role to play in providing and overseeing drug safety. They must examine all information pertaining to drugs, from development to patient use, and they should also take the monitoring system and drug safety assessment into account. The exchange of information between the pharmaceutical business and the drug regulatory authority plays a crucial role in improving communication [26].

WHO Quality Control and Safety Pharmaceuticals: Group: The Quality Assurance and Safety: Medicines Team at WHO is responsible for advising and assisting nations with drug safety issues. The department's stated objective is "to help save lives and improve health by closing the huge gap between the benefit that essential drugs have to offer and the reality that for millions of people–particularly the poor and dis advantaged– medicines are unavailable, unaffordable, unsafe or improperly used".

Monitoring Center of Uppsala (UMC): Following the notorious "Thalidomide disaster" in the early 1960s, several national programs were put in place to gather data on new drug dangers. In 1968, the WHO established a worldwide drug monitoring program. The UMC was established ten years later, in 1978, and given charge of overseeing and directing this initiative. WHO encourages pharmacovigilance at the national level in partnership with the WHO Collaborating Center for International Drug Monitoring (UMC) [27].

The Centers for National Pharmacovigilance (NPC): Additionally, by comparing drug spending with NPC policies and regulatory requirements, the majority of MOHs in their respective nations can fully or at least partially assist Pharmacovigilance National Centers. Furthermore, the WHO program for international drug monitoring has an unmatched opportunity to be thoroughly and suitably debated during the International Conference for Drug Regulation's (ICDRA) Annual Meetings of National Pharmacovigilance.

Additional Pharmacovigilance partners: Through collaboration and communication with the appropriate authorities, the media, advocacy organizations, and attorneys can directly or indirectly contribute to the development of pharmacovigilance policies and regulations [28].

Conclusion: Because it prevents, detects, and evaluates adverse reactions to pharmaceutical medicines intended for human use, pharmacovigilance is crucial for maintaining public health. It includes managing pharmaceuticals for human use over their entire life cycle while keeping safety in mind. Therefore, it is imperative that we emphasize the need for pharmacovigilance as an extension and completion of the analysis carried out on medications, starting with clinical trials when the medication is given for the first time in humans and not just after it has been launched. Pharmacovigilance is a crucial component in addressing the risks posed by the growing number of medications, each of which carries an unpredictably high risk of injury. It is imperative that any negative effects and toxicity, particularly those that were previously unknown, be documented, examined, and their importance clearly conveyed to those who are qualified to assess the data. By making sure that pharmaceuticals of high quality, safety, and effectiveness are used sensibly, the harm can be minimized. Additionally, when making therapeutic decisions, the patient's expectations and worries regarding results are taken into account. To achieve this objective and increase patient trust, make sure that medication usage risks are anticipated, effectively managed, and shared with regulatory bodies and other medical experts.

Reference:

[1] World Health Organization. Safety of medicines. A guide to detecting and reporting adverse drug reaction because health professionals need to take action. Geneva: World Health Organization; 2002.

[2] World Health Organization. Safety monitoring of medicinal products: guideline for setting up and running a Pharmacovigilance Centre. Uppsala: Uppsala Monitoring Centre, World Health Organization; 2000.

[3] The Uppsala monitoring system, WHO collaborating Centre for International Drug Monitoring World Health Organization; 2002.

[4] World Health Organization. The Importance of Pharmacovigilance – Safety Monitoring of Medicinal Products. Geneva: World Health Organization; 2002. Available from: http://www.apps.who.int/medicinedocs/pdf/s4893e/ s4893e.pdf. Last accessed 30th of April 2013.

[5] Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. JAMA 1998;279:1200-5.

[6] Strandell J, Norén GN, Hägg S. Key elements in adverse drug interaction safety signals: An assessment of individual case safety reports. Drug Saf 2013;36:63-70.

[7] Gallelli L, Staltari O, Palleria C, Di Mizio G, De Sarro G, Caroleo B. A case of adverse drug reaction induced by dispensing error. J Forensic Leg Med 2012;19:497-8.

[8] Patanè M, Ciriaco M, Chimirri S, Ursini F, Naty S, Grembiale RD, et al. Interactions among low dose of methotrexate and drugs used in the treatment of rheumatoid arthritis. Adv Pharmacol Sci 2013;2013:313858.

[9] De Vuono A, Scicchitano F, Palleria C, Russo E, De Sarro G, Gallelli L. Lack of efficacy during the switch from brand to generic allopurinol. J Forensic Leg Med 2013;20:540-2.

[10] De Vuono A, Palleria C, Scicchitano F, Squillace A, De Sarro G, Gallelli L. Development of skin rash during the treatment with generic itraconazole: Description of a case. J Pharmacol Pharmacother 2013 (In Press).

[11] Clarke A, Deeks JJ, Shakir SA. An assessment of the publicly disseminated evidence of safety used in decisions to withdraw medicinal products from the UK and US markets. Drug Saf 2006;29:175-81.

[12] Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Determinants of under reporting of adverse drug reactions: A systematic review. Drug Saf 2009;32:19-31.

[13] World Health Organization. Safety of medicines. A guide to detecting and reporting adverse drug reac tions why health professionals need to take action. Geneva: World Health Organization; 2002.

[14] World Health Organization. Safety monitoring of medicinal products: guideline for setting up and run ning a Pharmacovigilance Centre. Uppsala: Uppsala Monitoring Centre, World Health Organization; 2000.

[15] World Health Organization. The importance of pharmacovigilance. Safety monitoring of medicinal pro ducts. Uppsala Monitoring Centre, World Health Organization; 2002.

[16] Routledge P. 150 years of Pharmacovigilance. Lancet 1998;351:1200 1.

[17] Rich ML. Fatal case of aplastic anaemia following chloramphenicol therapy. Ann Intern Med 1950;33:1459.

[18] Wallerstein RO, Condit PK, Kasper CK, Brown JW, Morrison FR. Statewide study of chloramphenicol therapy and fatal aplastic anaemia. JAMA 1969;208:2045 50.

[19] Randall T. Thalidomide is back in the news, but in more favorable circumstances. JAMA 1990;263:1467 8.

[20] Van Grootheest K. The dawn of Pharmacovigilance. Intern J Pharm Med 2003;17:195 200.

[21] http://apps.who.int/medicinedocs/en/d/Js6164e/2.html, accessed on 30th November 2018.

[22] Beard K and Lee A. Introduction. In: Adverse drug reactions. London:Pharmaceutical Press, 2006; 1(2):1-22.

[23] Fortnum H, Lee A J, Rupnik B, Avery A. Survey to assess public awareness of patient reporting of adverse drug reactions in Great Britain. Journal of Clinical Pharmacy and Therapeutics, 2011; 37 (2):161-165.

[24] McLernon DJ, Bond C M, Lee A J, Watson M C, Hannaford PC, Fortnum H. (2011) Patient views and experiences of making adverse drug reaction reports to the Yellow Card Scheme in the UK. Pharmacoepidemiology and Drug Safety, 2011; 20(5):523 531.

[25] Anderson C, Krska J, Murphy E, Avery A. Assessing the usability of methods of public reporting of adverse drug reactions to the UK Yellow Card Scheme. Health Expectations. British Journal of Clinical Pharmacology, 2011; 72 (5):806-822.

[26] Roden S. An introduction to drug safety surveillance. In Research international Drug Surveillance Depertment (IDSD) Glaxo Group, ed. Drug safety: a shared responsibility, 199; 1-10.

[27] WHO-UMC. Being a member of the WHO Programme for International Drug Monitoring, 2009. [cited 19/1/2019]. Available from: http://who-umc.org/graphics/25642.pdf

[28] Safety of medicines in public health programmers: Pharmacovigilance an essential tool, World Health Organization, 2006.